Bernzott Capital Advisors Has $3.55 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bernzott Capital Advisors reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,580 shares of the medical equipment provider’s stock after selling 6,432 shares during the period. Bernzott Capital Advisors’ holdings in Zimmer Biomet were worth $3,547,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the third quarter valued at approximately $28,000. Bangor Savings Bank bought a new position in Zimmer Biomet in the third quarter valued at approximately $31,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Quarry LP bought a new position in Zimmer Biomet in the second quarter valued at approximately $53,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZBH has been the subject of a number of analyst reports. Truist Financial raised their price target on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada lifted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Oppenheimer reduced their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Finally, Evercore ISI reduced their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $108.86 on Friday. The stock has a market cap of $21.67 billion, a P/E ratio of 20.70, a PEG ratio of 1.79 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a 50 day simple moving average of $107.81 and a 200 day simple moving average of $107.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.65 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.